Mode
Text Size
Log in / Sign up

H. pylori prevalence 34.3% in French Guiana; gastric adenocarcinoma found in 1.65%One Third of Stomach Tests Show Hidden Bacteria Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that H. pylori prevalence is high in French Guiana, with low awareness and treatment rates, and associated gastric lesions are common.

This retrospective cohort study assessed the histological prevalence of Helicobacter pylori infection and associated gastric lesions in patients undergoing upper gastrointestinal endoscopy at Cayenne Hospital, French Guiana. Among 1,664 patients, 570 (34.3%) had histologically confirmed H. pylori infection. The infected cohort (n=545) was 57% women, mean age 49.5 years, and two-thirds were foreign-born.

Main indications for endoscopy were epigastric pain (53%), gastroesophageal reflux disease (20%), and abdominal pain (19%). Among infected patients, gastric adenocarcinoma was found in 1.65% and gastric precancerous lesions in 28.4%. Severe lesions requiring endoscopic surveillance were present in 6.6%.

Awareness of the H. pylori diagnosis was only 52% (95% CI 47.8–56.3), and just 48% (95% CI 44.7–53.2) received eradication therapy. Loss to follow-up was 19% (95% CI 15.8–22.6).

Limitations include the retrospective design and single-center setting, which may limit generalizability. No safety data were reported. Clinicians should recognize the high prevalence of H. pylori and associated gastric lesions in this population and the need to improve awareness and treatment rates.

Imagine getting a checkup for a stomach ache. You expect a simple answer. Instead, doctors find a hidden invader waiting inside.

This bacteria is common but dangerous. It causes ulcers and raises cancer risk. Many people live with it without knowing.

Why Stomach Bacteria Matter Now

In French Guiana, the numbers are higher than in other places. Socioeconomic factors play a big role in how it spreads.

Immigration patterns and limited healthcare access make things harder. This region faces unique challenges compared to mainland France.

Gastric cancer ranks high in both cases and deaths worldwide. It is the fifth most common cancer globally.

Finding the infection early is the best defense. But knowing you have it is only the first step.

The Hidden Danger Inside

Think of this bacteria like a key in a lock. It fits into the stomach lining and causes damage over time.

It creates inflammation that can turn cells abnormal. This process takes years, often decades, to show symptoms.

Some people feel nothing until the damage is severe. Others suffer from constant pain or indigestion.

Doctors saw epigastric pain in more than half the group. Reflux and general abdominal pain were also common.

What the Data Reveals

Researchers looked at tissue samples from 1,664 patients. They found the bacteria in 570 of those people.

That equals 34.3% of everyone tested. This is a very high rate for any region.

Most patients were around 50 years old. Two-thirds of them were born outside the territory.

This doesn't mean this treatment is available yet.

The findings were not just about the infection itself. Nearly one-third of patients had precancerous lesions.

Severe lesions requiring surveillance appeared in 6.6% of cases. A small number already had stomach cancer.

Why Follow-Up Often Fails

Diagnosis is only half the battle. The second half is making sure patients get treated.

Only 52% of patients knew they had the infection. Almost half received the therapy to clear it.

This gap leaves many people at risk. Nineteen percent were lost to follow-up entirely.

Systemic issues often cause these gaps. Language barriers and trust issues can play a part.

Patients need clear communication about next steps. Without it, the diagnosis becomes meaningless.

What Comes Next for Care

Healthcare systems must track patients better. Simple reminders or dedicated coordinators could help.

More research is needed to understand the barriers. We need to know why people drop out of care.

This study was retrospective and focused on one hospital. Results might differ in other locations.

Future trials will test better ways to reach patients. Approval for new treatments takes time and testing.

The goal is to stop cancer before it starts. Clearing the bacteria reduces that risk significantly.

Patients should talk to their doctors about symptoms. Stomach pain should never be ignored.

Early detection saves lives. But detection means nothing without follow-through.

We need a system that catches everyone. Then we can ensure they get the help they need.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionHelicobacter pylori (H. pylori) infects approximately half of the world’s population and is more prevalent in developing countries. It is a major risk factor for gastric cancer, which ranks fifth worldwide in both incidence and mortality. French Guiana is a French overseas territory located in the Amazon region and presents several characteristics that may favor H. pylori transmission compared with mainland France, including immigration from neighboring low-income countries, widespread socioeconomic vulnerability, a limited number of specialized healthcare professionals. In addition, the incidence of gastric cancer is high in this territory. However, the prevalence of H. pylori infection in this territory remains unknown. The aim of this study was to determine the histological prevalence of H. pylori infection in gastric biopsies, describe the clinical and histological characteristics of infected patients, and assess follow-up outcomes after diagnosis.Patients and methodsA retrospective study was conducted at Cayenne Hospital from January to December 2023 among patients with histologically confirmed H. pylori infection.ResultsHelicobacter pylori was detected in 570 of 1,664 patients (34.3%). Among these, 545 infected patients were included in the analysis, of whom 57% were women. The mean age was 49.5 years. Two-thirds of the patients were foreign-born. The main indications for upper gastrointestinal endoscopy were epigastric pain (53%), gastroesophageal reflux disease (20%), and abdominal pain (19%). Histological examination revealed gastric adenocarcinoma in 1.65% of cases and gastric precancerous lesions in 28.4%, including 6.6% severe lesions requiring endoscopic surveillance. Regarding follow-up, only 52% (95% CI 47.8–56.3) of patients were aware of their diagnosis and 48% (95% CI 44.7–53.2) received eradication therapy, while 19% (95% CI 15.8–22.6) were lost to follow-up.ConclusionThe histological prevalence of H. pylori infection was 34.3%. Despite the presence of gastric precancerous lesions in nearly one-third of patients, post-diagnosis follow-up remained inadequate.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.